https://www.biopharmadive.com/news/hospitalized-gene-therapy-patient-triggers-sarepta-sell-off/560546/
Hospitalized gene therapy patient triggers Sarepta sell off | BioPharma Dive
An erroneous report of rhabdomyolysis in a patient enrolled in a Duchenne trial was the latest safety worry to send shares in a gene therapy biotech spiraling.
gene therapybiopharma dive
https://www.statnews.com/2025/08/21/sarepta-gene-therapy-families-left-behind/
Rare disease patients left adrift after Sarepta gene therapy exit | STAT
Oct 10, 2025 - After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without long-promised treatments.
rare disease patientsleftgene
https://www.biopharmadive.com/news/pfizer-duchenne-gene-therapy-phase-3-sarepta/592936/
Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial | BioPharma Dive
late stage duchennepfizer
https://www.statnews.com/2025/07/18/sarepta-elevidys-deaths-duchenne-muscular-dystrophy-dmd-mothers-research-progress/
Sarepta gene therapy deaths must not halt Duchenne progress | STAT
Jul 21, 2025 - We’ve come so far against Duchenne, two mothers say. Despite recent setbacks, we must keep going — and save room for risks.
sarepta gene therapydeaths
https://www.statnews.com/2025/10/10/sarepta-gene-therapy-limb-girdle-muscular-dystrophy/
Sarepta to seek approval for gene therapy in rare muscular dystrophy | STAT
Oct 10, 2025 - Sarepta says it has what could be the first gene therapy for limb girdle muscular dystrophy. But getting through the FDA may be tough.
seek approvalgene therapyrare